AWS Health Innovation Podcast

Heart failure affects over 60 million people worldwide, yet monitoring blood pressure inside the heart remains an invasive, complex procedure. In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Filip Peters, CEO of Acorai, about their groundbreaking non-invasive SAVE Sensor System that combines multiple sensing technologies to measure intracardiac pressures - potentially transforming how we manage heart failure. 1. How did Filip transition from finance to healthcare technology? * Drawing from his background in machine learning and financial technology, Filip identified an opportunity to apply advanced analytics to cardiac monitoring. His transition exemplifies how cross-industry expertise can drive healthcare innovation. 2. What makes the SAVE Sensor System unique? * The system integrates four distinct sensor types - seismic, acoustic, visual, and electrical - creating a comprehensive approach to non-invasive cardiac monitoring. This novel combination enables detailed measurement of intracardiac pressures without invasive procedures. 3. How does Acorai's technology impact patient care? * By enabling frequent, non-invasive pressure monitoring, healthcare providers can track heart failure progression more effectively. This capability supports earlier interventions and more precise treatment adjustments, potentially improving outcomes for millions of patients. 4. What considerations went into the device design? * Acorai prioritized portability and user experience, creating an intuitive interface that integrates seamlessly with existing hospital workflows. This practical approach addresses key adoption barriers in clinical settings. 5. What milestones indicate Acorai's market potential? * The company has expanded operations across six countries and received FDA Breakthrough Device Designation, demonstrating strong market validation and regulatory progress. These achievements reflect growing confidence in Acorai's innovative approach. Learn more about Acorai at https://acorai.com/ [https://acorai.com/] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]

The complex relationship between bacteria and medication efficacy represents one of medicine's most overlooked frontiers. In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, GenAI Leader for Health & Bio at AWS Startups, speaks with Nik Sharma (CEO and Co-Founder) and Muhannad Alomari (CTO and Co-Founder) of BioCorteX. Their groundbreaking work in computational drug-bacteria interaction analysis is reshaping our understanding of personalized medicine and drug development. 1. What inspired BioCorteX's approach to pharmaceutical development? * People living with diseases cannot wait. Drawing from tried and tested engineering methodology, BioCorteX applies sophisticated engineering principles to transform drug development success rates by exploring the drug-bacteria interactions. This cross-industry innovation demonstrates how established engineering practices can revolutionize pharmaceutical outcomes. 2. What role does evolutionary biology play in BioCorteX's research methodology? * The company's approach is fundamentally built on the fact that mitochondria – the power house of cells – are ex-bacteria. This deep historical connection provides crucial insights into how bacterial interactions influence medication responses across diverse populations. 3. How does BioCorteX manage the complexity of human-bacterial interactions? * Understanding biology is one of the most complex tasks that humanity has ever attempted to tackle , with human bacteria interactions that far exceeds the number of stars in our galaxy. Their proprietary Carbon Mirror technology employs advanced emulation technologies to analyze drug-bacteria relationships at an unprecedented scale. This in-silico approach enables the exploration of complex interactions that traditional laboratory methods simply cannot possibly capture. 4. What makes BioCorteX's data approach unique in pharmaceutical development? * The Carbon Knowledge platform leverages 15 million samples from 165 different geopolitical regions worldwide, enabling highly accurate drug trial outcome predictions. The scale and geographical breadth of this highly curated data help optimize clinical trials and enhance success rates for pharmaceutical companies. 5. How does BioCorteX maintain efficiency with a lean team structure? * Operating with just twelve team members, BioCorteX maintains an strong and radically transparent culture where everyone codes while partnering with major industry players. Their focus on scalable output and revenue generation challenges traditional startup growth models. 6. What does BioCorteX's future in personalized medicine look like? * The recent partnership with Tempus demonstrates BioCorteX's commitment to advancing personalized medicine. Their technology platform is positioned to fundamentally change how pharmaceutical companies approach drug development and patient care particularly when moving assets across regions i.e China to Global. Learn more about BioCorteX at https://BioCorteX.com/ [https://BioCorteX.com/] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]

What if you could peer into the future of a clinical trial before enrolling a single patient? In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, sits down with Orr Inbar, Co-Founder & CEO of QuantHealth, to explore their groundbreaking platform that's revolutionizing drug development through clinical trial simulation. Their technology is transforming how pharmaceutical companies evaluate and advance potential therapies. 1. How is QuantHealth reshaping pharmaceutical research? * By leveraging an extensive database of 350 million patient records and sophisticated AI models, QuantHealth's platform achieves an impressive 86% accuracy in predicting trial outcomes. This capability directly addresses the industry's persistent challenges of rising costs and high failure rates. 2. What fundamental industry challenges does QuantHealth address? * The pharmaceutical industry struggles with average development costs of $3 billion and timelines exceeding a decade. Modern precision medicine requirements have added new layers of complexity to the drug development process, making traditional approaches increasingly challenging. 3. How did QuantHealth evolve during the pandemic era? * Born during COVID-19, QuantHealth developed an AI-driven solution that effectively bridges the critical gap between preclinical and clinical stages. Their platform now processes thousands of trials annually, demonstrating remarkable precision in predicting outcomes. 4. What makes QuantHealth's technical approach unique? * The platform combines biological knowledge graphs with deep learning models to create digital twins of both drugs and patients. This innovative approach spans more than 50 medical indications and multiple treatment modalities, enabling comprehensive trial simulation. 5. What real-world impact has QuantHealth demonstrated? * Through partnerships with major pharmaceutical companies, QuantHealth has helped increase trial success rates by 15% while simultaneously reducing development timelines. Their simulation technology has made previously unfeasible trials possible. Learn more about QuantHealth's innovative approach to clinical trial optimization at quanthealth.ai [https://quanthealth.ai/] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]

From developing advanced technology for astronauts to revolutionizing medical device connectivity, every founders' innovation journey includes unexpected twists and turns. In this episode of the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups at AWS, explores the transformative world of medical device cloud solutions with Alex Condon, COO and Co-founder of Galen Data. Their discussion reveals how Galen Data is helping medical device companies achieve FDA-compliant cloud connectivity in a fraction of the traditional time. 1. How did the transition from NASA contracting to medical devices shape Galen Data's vision? * Alex's experience in NASA contracting revealed striking parallels between spaceflight and medical device compliance requirements. This unique perspective helped shape Galen Data's approach to creating simplified, yet robust cloud infrastructure specifically for healthcare technology. 2. What key challenges do medical device companies face in today's market? * Complex EHR integrations and stringent cybersecurity requirements create significant barriers to market entry. Galen Data addresses these challenges through standardized solutions and comprehensive expert support, enabling faster deployment while maintaining compliance. 3. How does Galen Data adapt its platform for different company sizes? * The platform's configurable nature allows it to serve both startups and enterprise-level organizations effectively. Each implementation is tailored to address specific organizational needs while maintaining regulatory compliance and operational efficiency. 4. What factors contributed to Galen Data's successful acquisition? * Detailed documentation practices and strategic relationship building proved crucial in the acquisition by Luxera Capital Partners. The company's organized approach to compliance and security documentation demonstrated significant value during the exit process. 5. What sets Galen Data apart in the medical device industry? * Their commitment to genuine community engagement and customer success has fostered lasting partnerships beyond traditional business relationships. This approach has established Galen Data as a trusted partner in medical technology innovation. Learn more about Galen Data's innovative cloud platform for medical devices at galendata.com [https://galendata.com] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]

Guy Spigelman, EMEA Healthcare and Life Sciences Startups lead at AWS, sits down with Michel van Harten MD, CEO of myTomorrows, to explore how artificial intelligence is revolutionizing clinical trial recruitment. myTomorrows is transforming the patient-trial matching process, reducing hours of manual screening to mere minutes through sophisticated AI automation - all while maintaining exceptional accuracy standards. 1. How did a practicing physician become a digital health innovator? * Driven by firsthand experiences with treatment access barriers, Michel van Harten MD, transitioned from clinical practice to leading myTomorrows, combining medical expertise with technological innovation to solve healthcare delivery challenges. 2. What makes myTomorrows' platform unique in the clinical trial space? * The platform leverages advanced AI to create seamless connections between patients, physicians, and clinical trials, achieving an impressive 98% accuracy rate while reducing physician screening time by over 90%. 3. How does company culture contribute to patient impact? * Monthly patient speakers and mission-focused initiatives keep their 110-person team deeply connected to their purpose. This values-driven approach helps attract top talent while maintaining sustainable growth. 4. What is the global reach of myTomorrows' solution? * Operating across 125 countries with 2,200+ physicians, the platform has facilitated treatment access for nearly 15,000 patients through expanded access programs and clinical trial matching. 5. How has myTomorrows evolved from startup to scale-up? * Through strategic pivots and technological advancement, myTomorrows has built a sustainable growth model, positioning themselves for growth equity funding and continued market expansion. Learn more about myTomorrows at https://mytomorrows.com/ [https://mytomorrows.com/] Get in touch with AWS here [https://aws.amazon.com/contact-us/?trk=d7b08691-7f65-4c28-8b4e-13f1db4e310c&sc_channel=el] to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. [https://pulse.buildon.aws/survey/4LZ17IYI]